Apellis Pharmaceuticals Says All Reported Events Were Observed In Real-World Use Between 7-13 Days After The First Injection; Rare Events Of Idiopathic Orbital Inflammatory Disease With Retinal Vasculitis Reported In Real World At Estimated Rate Of About 0.01% Per Injection
Portfolio Pulse from Happy Mohamed
Apellis Pharmaceuticals reported that all events were observed in real-world use between 7-13 days after the first injection. Rare events of IOI with retinal vasculitis were reported in the real world at an estimated rate of about 0.01% per injection.
July 17, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals reported rare events of IOI with retinal vasculitis at an estimated rate of 0.01% per injection. This could potentially impact the company's reputation and sales.
The report of rare events of IOI with retinal vasculitis could potentially harm the reputation of Apellis Pharmaceuticals and affect the sales of their products. This is because such events could raise concerns about the safety and efficacy of their products, leading to decreased demand.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100